Mark D. Pegram, MD, director of the Breast Cancer Oncology Program, Stanford Women’s Cancer Center, co-director of Molecular Therapeutics Program, Stanford Medicine, discusses a phase II trial looking at ONT-380 in HER2+ breast cancer.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More